Abstract: Brooke-Spiegler syndrome (BSS; OMIM 605041) is an autosomal dominant condition characterized by skin appendageal neoplasms including cylindromas, trichoepitheliomas, and/or spiradenomas. In 1996, the gene locus for BSS was mapped to 16q12-13, and, in 2000, mutations in the cylindromatosis (CYLD) gene were determined to cause BSS, familial cylindromatosis (FC; OMIM 132700) and multiple familial trichoepithelioma type 1 (MFT1; OMIM 601606). The CYLD gene encodes an enzyme with deubiquitinase activity. To date, a total of 95 different diseases-causing mutations have been published for the CYLD gene. A summary of mutations identified in Hungarian patients and a review of previously published mutations are presented in this update. The majority of the sequence changes are frameshift (48%), nonsense (27%), missense (12%) and splice-site (11%) mutations; however, two in-frame deletions have also been reported Most mutations are located in exons 9-20. Analysis of the identified CYLD gene mutations and the observed BSS, FC and MFT1 clinical phenotypes of the patients revealed significant genotype-phenotype correlations. Elucidation of these genotype-phenotype correlations is critical for the diagnosis of these rare monogenic skin diseases. In addition, characterized correlations may promote the understanding of their mechanisms and may hopefully contribute to the development of future therapeutic modalities. 
3 BACKGROUND Brooke-Spiegler syndrome (BSS, OMIM 605041) is a rare monogenic skin disease (genodermatosis) characterized by the development of a wide variety of benign skin appendageal tumors, such as cylindromas, trichoepitheliomas and/or spiradenomas [Brooke, 1892; Spiegler, 1899] . The first symptoms of BSS are small skin-colored papules, which occur in childhood and adolescence [EVANS, 1954; Sima et al., 2010] . These tumors grow slowly in size and continue appear throughout the lifetime of the patient [Blake and Toro, 2009] . Expression of the papules exhibits wide variation among and within affected families [Poblete et al., 2002] .
Cylindromas are slowly growing benign tumors that are usually located on the scalp and face.
Typically, they appear as multiple turban-like protrusions on the scalp, which are also referred as turban tumors [Uede et al., 2004] . Cylindromas are histologically characterized by dermal nodules of epithelial cells: large cells with abundant cytoplasm occur at the center of the tumors, where as small basaloid cells occur at the periphery. The cells are lined by membranelike basement material and arranged in a -jigsaw puzzle‖ pattern [Lian and Cockerell, 2005] .
Cylindromas express hair keratins [Massoumi et al., 2006] .
Trichoepitheliomas are small benign skin-colored tumors and are typically present at the center of the face, mostly around the nose, periorbitally and in the nasolabial folds [Uede et al., 2004] . Histologically, trichoepitheliomas are characterized by basaloid cells with peripheral palisades that are arranged in nests or cribriform patterns surrounded by dense stroma and fibroblasts .
Spiradenomas are purple benign nodular tumors, which are usually located on the trunk or limbs [Uede et al., 2004] . Histologically, spiradenomas are composed of large tumor nests comprising two types of epithelial cells . Large light-colored cells with   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 4 abundant cytoplasm at the center of the nests are surrounded by small darker cells at the periphery Michal et al., 1999] . Spiradenomas rarely become malignant but can transform into spiradenocarcinomas [Cooper et al., 1985; Engel et al., 1991; Chou et al., 2004] . Hybrid tumors can also occur, such as spiradenocylindromas, which exhibit the characteristics of both cylindromas and spiradenomas [Kazakov et al., 2005; Kazakov et al., 2008; Pizinger and Michal, 2000] .
BSS is transmitted as an autosomal dominant condition affecting males and females equally [GUGGENHEIM and Schnyder, 1961] . BSS and its phenotypic variants were independently mapped to chromosome 16q12-q13 by several groups [Fenske et al., 2000; Biggs et al., 1995; Biggs et al., 1996; Takahashi et al., 2000] . Within the mapped region, the cylindromatosis gene (CYLD) was identified as the causative gene responsible for the development of the disease Bignell et al., 2000] . The CYLD gene (GenBank accession number NM_015247) spans 56 kb and contains 20 exons, the first 3 of which are untranslated, and 19 introns. Of the 17 known splice variants, 13 affect protein coding regions, and the remaining produce non-coding transcripts (http://ensemble.org). The tumor suppressing CYLD gene encodes an enzyme with deubiquitinase activity. The CYLD enzyme posttranslationally modifies its target proteins by removing Lys63-linked ubiquitin chains [Kovalenko et al., 2003] . The protein interacts with several members of the NF-ĸB signaling pathway, including the TRAF2, TRAF6, NEMO and BCL3 proteins, acting as a negative regulator [Hutti et al., 2009] .
In 2000, the first 21 mutations of the CYLD gene were identified in the affected members of 21 families with familial cylindromatosis (FC; OMIM 132700), a clinical variant of BSS [Bignell et al., 2000] . Since 2000, several reports have described mutations in the CYLD gene in different cases from around the world [Blake and Toro, 2009] . In addition to BSS and FC, mutations of the CYLD gene have also been reported in patients with multiple familial   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 5 trichoepithelioma type 1 (MFT1; OMIM 601606) . BSS, FC and MFT1 show overlapping phenotypic features: some BSS patients develop multiple skin appendage tumors including cylindromas, trichoepitheliomas, and spiradenomas, whereas patients with FC develop only cylindromas, and patients with MFT1 develop only trichoepitheliomas (Table I) [Brooke, 1892] [Spiegler, 1899; Ancell, 1842; Fordyce, 1892; Zhang et al., 2004] . BSS, FC and MFT1 were originally described as distinct clinical entities, but due to their overlapping clinical symptoms and their manifestation within the same families, they are now considered as a clinical variants that represent a phenotypic spectrum of a single entity Welch et al., 1968; Young et al., 2006; Oranje et al., 2008] . [Bignell et al., 2000; Bowen et al., 2005; Grossmann et al., 2013; Linos et al., 2011; Lv et al., 2008; Kacerovska et al., 2013; Saggar et al., 2008; Van den Ouweland et al., 2011; Oiso et al., 2004; Zhang et al., 2006; Kazakov et al., 2009; Kazakov et al., 2011; Nagy et al., 2013] . Therefore, it has been hypothesized that BSS, FC and MFT1 are not different disease entities, but represent a phenotypic spectrum of the same disease.
SUMMARY OF HUNGARIAN BSS PATIENTS
In Hungary, mutation screening for the CYLD gene has been available since 2010. Screening has been performed with direct sequencing of all coding regions and flanking introns of the CYLD gene. Once a putative causative variant was identified in a patient, the available, [Linos et al., 2011] .
Pedigree II contains 21 affected family members from seven generations, all of whom exhibit severe symptoms also located on their scalp, middle face and trunk [Grossmann et al., 2013] .
Histological investigation of excised tumors confirmed the presence of cylindromas, trichoepitheliomas and spiradenomas for the affected members of both pedigrees, establishing the diagnosis of BSS for both families. Mutation screening of the CYLD gene identified a novel missense mutation (c.2613C>G, p.His871Gln) in Pedigree I and a recurrent nonsense mutation (c.2806C>T, p.Arg936X) in Pedigree II [Grossmann et al., 2013; Linos et al., 2011] .
The results of functional characterization indicated that the newly identified missense mutation from Pedigree I leads to increased ubiquitination of NEMO by modifying the deubiquitinating activity of the CYLD protein [Linos et al., 2011] . Since nonsense mutation in Pedigree II is recurrent, functional analysis was not carried out for this family. However, the same mutation was identified in an Anglo-Saxon pedigree with mild BSS symptoms. We performed haplotype analysis for these two geographically distant pedigrees and found that the mutations resulted from two independent mutational events, suggesting that is the mutations represent a mutational hotspot on the CYLD gene [Grossmann et al., 2013] . Our results correlate well with the data reported in the literature supporting the assumption that this is a mutational hotspot on the gene: the c.2806C>T, p.Arg936X nonsense mutation has been described in all three allelic variants in the disease spectrum caused by CYLD mutations   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   7 and results in different symptom severity as well as the development of different clinical variants [Bignell et al., 2000; Bowen et al., 2005; Grossmann et al., 2013; Saggar et al., 2008; Kazakov et al., 2009; Nagy et al., 2013] . [Bignell et al., 2000; Grossmann et al., 2013; Saggar et al., 2008; Nasti et al., 2009; Ying et al., 2012 ;   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 8 Liang et al., 2008; Zheng et al., 2004] , whereas the rest (66%) occur within the region spanning exons 12-20 [Bignell et al., 2000; Bowen et al., 2005; Grossmann et al., 2013; Lv et al., 2008] [Saggar et al., 2008; Oiso et al., 2004; Reuven et al., 2013; Chen et al., 2011; Salhi et al., 2004; Melly et al., 2012; Heinritz et al., 2006] . Exon 17 is a mutational hotspot, containing 20% of all identified frameshift mutations [Bignell et al., 2000; Bowen et al., 2005; Grossmann et al., 2013; Lv et al., 2008; Saggar et al., 2008; Oiso et al., 2004] . Only a quarter of the frameshift mutations (27%) are recurrent, i.e., having been reported by at least two studies [Sima et al., 2010; Poblete et al., 2002; Bignell et al., 2000; Bowen et al., 2005; Grossmann et al., 2013; Saggar et al., 2008; Oiso et al., 2004; Scheinfeld et al., 2003; Hester et al., 2013] . In general, different frameshift mutations can lead to the development of the different allelic variants and show phenotypic diversity (Figure 4 ) [Bignell et al., 2000; Saggar et al., 2008; Nasti et al., 2009; Ying et al., 2012; Liang et al., 2008; Scheinfeld et al., 2003; Hester et al., 2013; Scholz et al., 2010] .
VARIANTS OF THE CYLD GENE
Nonsense mutations causing truncation and, thus, CYLD protein dysfunction are also common, accounting for one quarter (27%) of the CYLD mutations identified so far ( Figure   2 ). The distribution of nonsense mutations is also unequal in the CYLD gene (Figure 3 ). One third of the nonsense mutations occur within the region spanning exons 9-11 [Sima et al., 2010; Bignell et al., 2000; Bowen et al., 2005; Grossmann et al., 2013; Linos et al., 2011; Lv et al., 2008; Kacerovska et al., 2013; Saggar et al., 2008; Van den Ouweland et al., 2011; Kazakov et al., 2009; Almeida et al., 2008] , while the majority (72%) are located within the region spanning exons 12-20 [Sima et al., 2010; Bignell et al., 2000; Zhang et al., 2004; Young et al., 2006; Oranje et al., 2008; Bowen et al., 2005; Grossmann et al., 2013; Oiso et al., 2004; Kazakov et al., 2009; Nagy et al., 2013; Nagy et al., 2012; Zheng et al., 2004; Chen et al., 2011; Almeida et al., 2008] . This latter region does not seem to contain a further mutational hotspot. It is of interest to note that 25% of the identified nonsense mutations   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 9 affect glutamine amino acid residues within the CYLD protein, replacing them with stop codons [Sima et al., 2010; Bignell et al., 2000; Grossmann et al., 2013; Zheng et al., 2004; Chen et al., 2011; Almeida et al., 2008] . Nearly half of the nonsense mutations (40%) are recurrent [Sima et al., 2010; Bignell et al., 2000; Oranje et al., 2008; Bowen et al., 2005; Grossmann et al., 2013; Linos et al., 2011; Lv et al., 2008; Kacerovska et al., 2013; Saggar et al., 2008; Van den Ouweland et al., 2011; Oiso et al., 2004; Zhang et al., 2006; Kazakov et al., 2009; Kazakov et al., 2011; Nagy et al., 2013; Zheng et al., 2004; Chen et al., 2011] . In general, nonsense mutations -even the same mutation in different individuals -lead to the development of the different clinical variants; thus, nonsense mutations have been associated with the highest phenotypic diversity (Figure 4) [Bignell et al., 2000; Bowen et al., 2005; Grossmann et al., 2013; Linos et al., 2011; Lv et al., 2008; Kacerovska et al., 2013; Saggar et al., 2008; Van den Ouweland et al., 2011; Oiso et al., 2004; Zhang et al., 2006; Kazakov et al., 2009; Kazakov et al., 2011; Nagy et al., 2013] .
Missense mutations account for 12% of all mutations identified on the CYLD gene (Figure 2 ).
The distribution of missense mutations is also unequal on the CYLD gene (Figure 3 ): all are located within the region spanning exons 12-20 [Sima et al., 2010; Hu et al., 2003; Grossmann et al., 2013; Linos et al., 2011; Lv et al., 2008; Kacerovska et al., 2013; Saggar et al., 2008; Van den Ouweland et al., 2011; Kazakov et al., 2009; Nagy et al., 2012; Zheng et al., 2004; Almeida et al., 2008; Espana et al., 2007; Wang et al., 2010; Zuo et al., 2007] . Only a quarter (27%) of these are recurrent mutations [Sima et al., 2010; Hu et al., 2003; Grossmann et al., 2013; Saggar et al., 2008; Kazakov et al., 2009] . In general, missense mutations of the CYLD gene have been associated with less phenotypic diversity that other kinds of mutations: three quarters (73%) have been reported in MFT1 only (Figure 4) [Nagy et al., 2012; Zheng et al., 2004; Almeida et al., 2008; Espana et al., 2007; Wang et al., 2010; Zuo et al., 2007] . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 10 Splice-site mutations account for 11% of all mutations (Figure 2 ). The distribution of the splice-site mutations is also unequal (Figure 3 ): all of them occur within the region spanning exons 10-18 [Bignell et al., 2000; Grossmann et al., 2013; Kacerovska et al., 2013; Van den Ouweland et al., 2011; Kazakov et al., 2011; Nasti et al., 2009; Ying et al., 2012; Liang et al., 2008; Huang et al., 2009; Ly et al., 2004] . Less than a quarter (18%) are recurrent [Bignell et al., 2000; Grossmann et al., 2013; Van den Ouweland et al., 2011; Kazakov et al., 2011] . In general, splice-site mutations can lead to the development of different clinical variants and show phenotypic diversity (Figure 4) Van den Ouweland et al., 2011; Nasti et al., 2009; Liang et al., 2008; Huang et al., 2009] .
In addtion, two in-frame deletions have also been reported: these mutations are located within 
ETHNIC VARIATION
Mutations of the CYLD gene have been reported among patients with Irish, Japanese, Spanish, German, Algerian, Turkish, Hungarian, Slovakian, Italian, Scandinavian, Taiwanese, Turkish, Canadian and African backgrounds [Bowen et al., 2005; Kacerovska et al., 2013; Saggar et al., 2008; Nagy et al., 2013; Nagy et al., 2012; Nasti et al., 2009; Salhi et al., 2004; Huang et al., 2009; Amaro et al., 2010] . However, the majority of the published mutations are reported for patients from the UK, USA and China [Bignell et al., 2000; Lv et al., 2008; Ying et al., 2012; Liang et al., 2008; Zheng et al., 2004; Chen et al., 2011; Wang et al., 2010; Zuo et al., 2007] . Recurrent mutations have been detected in patients living in geographically distant regions: the c.1112C/A p.S371X nonsense mutation was identified in Irish, African American, Slovakian and Chinese patients [Bowen et al., 2005; Linos et al., 2011; Lv et al., 2008 ;   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 11 Kacerovska et al., 2013] and the c.2806C/T p.R936X nonsense mutation was detected in Canadian, American, Anglo-Saxon and Hungarian patients [Bignell et al., 2000; Bowen et al., 2005; Nagy et al., 2013] . The appearance in geographically distant patients might suggest that these recurrent mutations are located in mutational hotspots of the CYLD gene [Nagy et al., 2013] . Haplotype analysis of patients carrying the same recurrent mutation indicated a common ancestor for some patients [Bignell et al., 2000] and independent mutational events for others [Nagy et al., 2013] .
A comparison of ethnicity and allelic variation revealed geographical differences. The clinical phenotype of MFT1 was observed mostly in individuals from China but also in African, AfroAmerican, Taiwanese, Algerian, Turkish, Italian and Spanish patients [Lv et al., 2008; Kacerovska et al., 2013; Liang et al., 2008; Zheng et al., 2004; Chen et al., 2011; Wang et al., 2010; Zuo et al., 2007] . The majority of patients exhibiting the FC clinical variant were from the UK and the USA, but some patients were from Italy and Ireland [Bignell et al., 2000; Bowen et al., 2005; Nasti et al., 2009] . Like FC, the majority of patients presenting the BSS clinical variant were from the UK and the USA; however, patients from Hungary, Slovakia, Italy, Scandinavia, Spain and Canada have also been reported [Bignell et al., 2000; Bowen et al., 2005; Kacerovska et al., 2013; Nagy et al., 2013; Nagy et al., 2012; Nasti et al., 2009] .
BIOLOGICAL RELEVANCE
The protein encoded by the CYLD gene (GenBank NP_056062), consisting of 956 amino acids with a molecular weight of approximately 120 kD, exhibits deubiquitinase activity. The CYLD protein plays a role in the posttranslational modification of several proteins by removing lysine 63-linked ubiquitin chains. Lysine 63-linked polyubiquitination affects the interactions among proteins by creating specific recognition sites for other proteins. However ,   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 12 the CYLD protein, which primarily deubiquitinates lysine 63-linked chains, can also process lysine 48-linked chains as well [Reiley et al., 2006; Komander et al., 2008] . The known interaction partners of the CYLD protein include TNF-receptor-associated factor proteins (TRAF2, TRAF6 and TRAF7) and the NEMO protein, a negative regulator of the NF-kB signaling pathway [Haglund and Dikic, 2005] . CYLD is involved in the regulation of several biological processes, such as cell proliferation and inflammation [Gao et al., 2008] .
The N-terminal of the CYLD protein can be divided into two regions based on the occurrence of the mutations: no mutations have been detected in the region encoded by exons 4 and 5, whereas the region encoded by exons 5-11 contains approximately one fifth (18%) of the mutations identified to date. The N-terminal of the CYLD protein contains three cytoskeletonassociated glycine rich domains (CAP-GLY), at which the CYLD protein connects to microtubules [Gao et al., 2008] . The N-terminal of the CYLD protein is highly conserved through evolution ( Figure 5 ). Mostly frameshift and nonsense mutations occur in this region, as well as the two known splice-site mutations [Sima et al., 2010; Bignell et al., 2000; Bowen et al., 2005; Grossmann et al., 2013; Kacerovska et al., 2013; Saggar et al., 2008; Kazakov et al., 2009] [Nasti et al., 2009; Liang et al., 2008; Zheng et al., 2004; Almeida et al., 2008; Ly et al., 2004] . Most frameshift mutations occur in the first (amino acids 127 to 203) and the third (amino acids 472 to 540) CAP-GLY domains, whereas most of the nonsense and splice-site mutations occur in the region of the third CAP-GLY domain (Figure 3 ). Frameshift and nonsense mutations occurring in this region have been identified for all clinical variants [Sima et al., 2010; Bignell et al., 2000; Bowen et al., 2005; Kacerovska et al., 2013; Saggar et al., 2008; Nasti et al., 2009; Liang et al., 2008; Zheng et al., 2004; Almeida et al., 2008] . The splice-site mutations of this region resulted in the development of the BSS or MFT1 clinical variants [Grossmann et al., 2013; Kazakov et al., 2009; Ly et al., 2004] . Missense mutation has not been detected at the N-terminal of the CYLD protein. 8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   13 The CYLD gene has changed relatively little through evolution: the similarity between the human and mouse genes is 94%, and the homology is especially high at the 3' end of the gene ( Figure 5 ). This region of the CYLD protein, encoded by exons 12-20, contains the ubiquitinspecific protease domain that is responsible for the deubiquitinase activity of the protein. This region contains the majority (82%) of identified CYLD mutations, including frameshift (72%), nonsense (72%) and splice-site (81%) mutations as well as all known missense mutations (Figure 3) . Mutations of this region are associated with high phenotypic diversity and can lead to the development of any of the three clinical variants of the CYLD mutation-caused spectrum. Functional studies of the identified mutations suggest that mutations of this region may decrease the deubiquitinase activity of the CYLD protein [Nagy et al., 2012] .
CLINICAL AND DIAGNOSTIC RELEVANCE
With respect to the clinical symptoms, FC and MFT1 represent the two extremes of the CYLD mutation-caused spectrum, where as BSS falls between these two (Table I ). All three clinical variants exhibit variable expression among and within affected families; however, the most extreme differences in the manifested phenotypes have been reported for BSS [Bowen et al., 2005; Zhang et al., 2006; Nagy et al., 2013] . The penetrance is high for all three clinical variants and increases with age.
The majority (82%) of CYLD mutations are located between exons 12 and 20, especially in and around exons 16 and 17 (16%) (Figure 1) . This finding has a significant diagnostic relevance, as mutation screening of affected individuals should start by examining this region.
If no mutation is identified in the coding regions and the flanking introns of exons 12-20, the screening can be expanded to exons 5-11. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 14 We suggest using direct sequencing for the screening method, as the mutation detection rate is high, estimated at 84% [Saggar et al., 2008] . With the identification of the causative mutation, prenatal as well as preimplantation genetic diagnosis can be offered to affected families, which, as symptoms of all clinical variants can be very stigmatizing, can have a meaningful impact on family planning [Nagy et al., 2013] .
Causative therapy is not currently available for BSS patients. However, recent investigation demonstrated that tumors with somatic CYLD mutation have impaired tropomyosin kinase (TRK) signaling. Treatment with small TRK inhibitor molecule, lestaurtinib, can reduce colony formation and proliferation of CYLD mutant tumor cells [Rajan et al., 2011] . These data may have huge clinical significance, since lestaurtinib treatment might be a novel therapeutic modality for patients suffering from symptoms caused by germline CYLD mutations.
GENOTYPE-PHENOTYPE CORRELATIONS
Genotype-phenotype correlations are difficult to establish, as all types of known CYLD mutation -frameshift, nonsense, missense and splice-site -lead to the development of each clinical variant of the CYLD mutation-caused spectrum.
For example, frameshift mutations of the CYLD gene have been identified for all clinical variants of the CYLD mutation-caused spectrum. Interestingly, most frameshift mutations occur in the region of exon 17 [Bignell et al., 2000; Bowen et al., 2005; Grossmann et al., 2013; Lv et al., 2008; Saggar et al., 2008; Oiso et al., 2004] .
In general, nonsense mutations of the CYLD gene exhibit the largest phenotypic diversity.
Some nonsense mutations (i.e., c.1112C/A p.S371X, c.2272C/T p.R758X and c.2806C/T p.R936X) have been detected in patients diagnosed with FC, BSS or MFT1 [Bignell et al., 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   15 2000; Bowen et al., 2005; Grossmann et al., 2013; Linos et al., 2011; Lv et al., 2008; Kacerovska et al., 2013; Saggar et al., 2008; Van den Ouweland et al., 2011; Oiso et al., 2004; Zhang et al., 2006; Kazakov et al., 2009; Kazakov et al., 2011; Nagy et al., 2013] .
Presumably, this is due to the fact that nonsense mutations are the most recurrent (40%) type of CYLD mutation [Sima et al., 2010; Bignell et al., 2000; Oranje et al., 2008; Bowen et al., 2005; Grossmann et al., 2013; Linos et al., 2011; Lv et al., 2008; Kacerovska et al., 2013; Saggar et al., 2008; Van den Ouweland et al., 2011; Oiso et al., 2004; Zhang et al., 2006; Kazakov et al., 2009; Kazakov et al., 2011; Nagy et al., 2013; Zheng et al., 2004; Chen et al., 2011] . As many recurrent nonsense mutations are due to de novo events, their frequency and location indicates mutational hotspots on the CYLD gene [Bignell et al., 2000; Nagy et al., 2013] . Patients carrying the same nonsense mutation from different mutational events often exhibit extreme differences in their clinical manifestations [Nagy et al., 2013] . These differences might be the consequences of yet unknown genetic factors that modify the development of the phenotype. Nonsense mutations are also responsible for the most variable expression within families [Bowen et al., 2005; Zhang et al., 2006; Nagy et al., 2013] . These differences might be explained by environmental and/or lifestyle factors. Further studies are needed to elucidate putative genetic, environmental or lifestyle factors that are responsible for the observed great variation in phenotype.
Missense mutations of the CYLD gene are more frequently associated only with MFT1 (73%) than the other types of mutations [Sima et al., 2010; Hu et al., 2003; Grossmann et al., 2013; Linos et al., 2011; Lv et al., 2008; Kacerovska et al., 2013; Saggar et al., 2008; Van den Ouweland et al., 2011; Kazakov et al., 2009; Nagy et al., 2012; Zheng et al., 2004; Almeida et al., 2008; Espana et al., 2007; Wang et al., 2010; Zuo et al., 2007] . Missense mutations also lead to the development of milder phenotype [Nagy et al., 2012] . This observation might be explained by the fact that missense mutations are distributed differently than the other types 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 16 of mutations: they are located only between exons 12-20 and not at all in the 5' end. In general, missense mutations are associated with low phenotypic diversity, as the majority of missense mutations result in the MFT1 phenotype [Nagy et al., 2012; Zheng et al., 2004; Almeida et al., 2008; Espana et al., 2007; Wang et al., 2010; Zuo et al., 2007] . Moreover, only 12% of missense mutations are recurrent [Sima et al., 2010; Hu et al., 2003; Grossmann et al., 2013; Saggar et al., 2008; Kazakov et al., 2009] .
Splice-site mutations of the CYLD gene can lead to the development of any clinical variant of the CYLD mutation-caused spectrum, but little is known about their phenotypic significance Van den Ouweland et al., 2011; Nasti et al., 2009; Liang et al., 2008; Huang et al., 2009] .
FUTURE PROSPECTS
The comparison of CYLD gene mutations and the observed clinical variation of the patients have already revealed significant genotype-phenotype correlations: nonsense mutations are associated with the highest phenotypic diversity and recurrence rate, while missense mutations are associated with mild symptoms and are strongly associated with the MFT1 phenotype. Future efforts might provide insight into the clinical significance of frameshift and splice-site mutations and further elucidate the mechanism of the different phenotypic variants of the CYLD mutation-caused spectrum. We believe that careful investigation of genotypephenotype correlations are necessary to promote better understanding of the BSS, FC and MFT1 clinical variants and provide insight into the underlying molecular mechanisms.
Genetic screening and the identification of disease-causing mutations have already had a significant impact on prenatal and preimplantation genetic diagnosis for family planning.
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